

# Influenza Vaccine Product List and Age Groups --- United States, 2020-2021 Season<sup>1</sup>

*DoD contracted NH vaccines (highlighted yellow), SH vaccine (highlighted blue); \*Direct Vendor Delivery (DVD) available vaccines (highlighted orange)*

Manufacturer	Trade Name (vaccine abbreviation) <sup>2</sup>	NDC	Presentation	Mercury (thimerosal) mcg Hg/0.5 mL	Ovalbumin mcg/0.5 mL	Age Group	CVX	CPT
Seqirus, Inc.	Afluria <sup>®1,4,5</sup> (IIV4)	33332-0220-20	0.25 mL single-dose syringe	0	< 0.5	6-35 mos	161	90685
		33332-0320-01	0.5 mL single-dose syringe	0	< 1	≥ 3 yrs	150	90686
		33332-0420-10	5 mL multi-dose vial (0.25 mL dose) <sup>4</sup>	12.25	< 0.5	6-35 mos	158	90687
		33332-0420-10	5 mL multi-dose vial (0.5 mL dose) <sup>4</sup>	24.5	< 1	≥ 3 yrs	158	90688
	Fluad <sup>®1,7</sup> (aIIV4)	70461-0120-03	0.5 mL single-dose syringe	0	< 1	≥ 65 yrs	205	90654
	Flucelvax <sup>®1</sup> (ccIIV4)	70461-0320-03	0.5 mL single-dose syringe	0	0	≥ 4 yrs	171	90674
		70461-0420-10	5 mL multi-dose vial	25	0		186	90756
GlaxoSmithKline	Fluarix <sup>®1,3</sup> (IIV4)	58160-0885-52	0.5 mL single-dose syringe <sup>3</sup>	0	≤ 0.05	≥ 6 mos	150	90686
	FluLaval <sup>®1,3</sup> (IIV4)	19515-0816-52	0.5 mL single-dose syringe <sup>3</sup>	0	≤ 0.3	≥ 6 mos	150	90686
Sanofi Pasteur, Inc.	Fluzone <sup>®1,6</sup> (IIV4)	49281-0520-25	0.25 mL single-dose syringe <sup>6</sup>	0	§§	6-35 mos	161	90685
		49281-0420-50	0.5 mL single-dose syringe <sup>6</sup>	0	§§		150	90686
		49281-0420-10	0.5 mL single-dose vial	0	§§	≥ 6 mos	150	90686
		49281-0633-15	5 mL multi-dose vial (0.25 mL dose) <sup>6</sup>	12.25	§§	6-35 mos	158	90687
		49281-0633-15	5 mL multi-dose vial (0.5 mL dose) <sup>6</sup>	25	§§	≥ 6 mos	158	90688
	Fluzone <sup>®</sup> High-Dose <sup>1,8</sup> (HD-IIV4)	49281-0120-65	0.7 mL single-dose syringe	0	§§	≥ 65 yrs	197	90662
	Fluzone <sup>®</sup> Southern Hemisphere <sup>1</sup> (SH-IIV4)	49281-0320-50	0.5 mL single-dose syringe	0	§§	≥ 6 mos	201	90686
Protein Sciences Corp.	FluBlok <sup>®1</sup> (RIV4)	49281-0720-10	0.5 mL single-dose syringe	0	0	≥ 18 yrs	185	90682
MedImmune	FluMist <sup>®1</sup> (LAIV4)	66019-0307-10	0.2 mL single-use intranasal sprayer	0	≤ 0.024	2-49 yrs	149	90672

- Vaccination providers should consult the FDA-approved prescribing information for 2020-2021 seasonal influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at: [www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states](http://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states)
  - IIV4 = egg-based quadrivalent inactivated influenza vaccine (injectable); where necessary to refer to cell culture-based vaccine, the prefix “cc” is used (e.g., ccIIV4); RIV4 = quadrivalent recombinant hemagglutinin influenza vaccine (injectable); aIIV4 = adjuvanted quadrivalent inactivated influenza vaccine.
  - Fluarix<sup>®</sup> (IIV4) and FluLaval<sup>®</sup> (IIV4) 0.5 mL dose is the same for adults and pediatrics.
  - Once the stopper of the Afluria<sup>®</sup> multi-dose vials are pierced the vial must be discarded within 28 days. No more than 10 doses (0.25 mL or 0.5 mL) should be withdrawn from the multi-dose vial.**
  - Afluria<sup>®</sup> is licensed for administration by PharmaJet<sup>®</sup> Stratis<sup>®</sup> Needle-Free Injection System for persons aged 18 through 64 years only.
  - Fluzone<sup>®</sup> Quadrivalent may be given to children aged 6 through 35 months as either the 0.25 mL dose or the 0.5 mL dose. No preference is expressed for one or the other dose volume for this age group. Persons aged ≥3 years should receive the 0.5 mL dose. No more than 10 doses (0.25 mL or 0.5 mL) should be withdrawn from the multi-dose vial.
  - Fluad<sup>®</sup> includes the MF59C.1 adjuvant (MF59<sup>®</sup>), a squalene based oil-in-water emulsion.
  - Quadrivalent inactivated vaccine high-dose: a 0.7-mL dose contains 60 µg of each vaccine antigen (180 µg total).
  - Recommendation of the CDC’s Advisory Committee on Immunization Practices (ACIP) for the 2020-2021 influenza season: routine annual influenza vaccination of all persons aged ≥6 months who do not have contraindications continues to be recommended. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended, and appropriate product is available.
- §§ Available upon request from Sanofi Pasteur (1-800-822-2463 or [MIS.emails@sanofipasteur.com](mailto:MIS.emails@sanofipasteur.com)).
- \* Direct Vendor Delivery (DVD) vaccines are available for purchase by MTFs. Refer to the Seasonal Influenza Program DHA-PI for information on the ordering process.